期刊文献+

阿德福韦酯治疗经拉米夫定治疗后YMDD变异的慢性乙型肝炎患者48周疗效及相关因素分析 被引量:2

Analysis of 48 weeks effect and related factors of adefovir in the treatment of chronic hepatitis B patients with YMDD variant after lamivudine treatment
下载PDF
导出
摘要 目的:探讨阿德福韦酯(ADV)治疗经拉米夫定(LAM)治疗后YMDD变异的慢性乙型肝炎患者48周疗效及相关因素。方法:收治经LAM治疗后YMDD变异的慢性乙肝患者100例,联合ADV治疗,观察治疗48周的疗效,分析相关因素。结果:48周HBV-DNA转阴、HBe Ag阳性患者e抗原转阴或转换和ALT复常者较未转阴者的基线HBV-DNA水平低,基线ALT水平≤IULN者48周可维持较高的ALT复常率和HBV-DNA转阴率,但48周HBe Ag阳性患者e抗原转阴或转换与基线ALT水平无相关性(P>0.05);基线HBV-DNA低水平、24周HBV-DNA转阴、12周YMDD变异转阴是48周疗效较好的预测因素。结论:对经LAM治疗后YMDD变异的慢性乙型肝炎患者,联合ADV治疗,其基线HBV-DNA低水平、24周HBV-DNA转阴、12周YMDD变异转阴是48周疗效较好的预测因素。 Objective:To explore the 48 weeks effect and related factors of adefovir(ADV) in the treatment of chronic hepatitis B patients with YMDD variant after lamivudine(LAM) treatment.Methods:100 patients with chronic hepatitis B and YMDD variant after lamivudine treatment were selected.They were treated with ADV.We observed the efficacy of the treatment for 48 weeks and analyzed the related factors.Results:Compared with those who did not turn negative,the baseline HBV-DNA level of patients with negative HBV-DNA and positive HBe Ag at 48 weeks and patients with e antigen turn negative or conversion and ALT recurrence was low.In patients of baseline ALT level less than or equal to IULN,48 weeks can maintain high ALT repetition rate and HBV DNA negative rate,but there was no correlation between the e antigen turn negative or conversion and baseline ALT level in patients with positive HBe Ag at 48 weeks(P〈0.05).The low level of baseline HBV-DNA,24 weeks HBV-DNA turning negative,and 12 weeks YMDD variant turn negative were the predictors of better curative effect in 48 weeks.Conclusion:For chronic hepatitis B patients with YMDD variant after lamivudine treatment,combined with ADV treatment,the low level of baseline HBV-DNA,24 weeks HBV-DNA turning negative,and 12 weeks YMDD variant turn negative were the predictors of better curative effect in 48 weeks.
作者 吴一芳
机构地区 潜江市二医院
出处 《中国社区医师》 2018年第8期65-66,共2页 Chinese Community Doctors
关键词 阿德福韦酯 拉米夫定 YMDD变异 慢性乙型肝炎 Adefovir Lamivudine YMDD variant Chronic hepatitis B
  • 相关文献

参考文献4

二级参考文献33

  • 1桂秀海.阿德福韦酯初治与挽救治疗拉米夫定耐药的慢性乙型肝炎观察[J].中国肝脏病杂志(电子版),2010,2(3):9-11. 被引量:2
  • 2张立,陈永春,王广宇,单巍,李晓玲,朱旅云.石家庄市部分职业人群血钙、磷与年龄、性别的关系[J].临床误诊误治,2006,19(9):87-88. 被引量:4
  • 3Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antirettroviral therapy: a randomized controlled trial[J]. JAM_A, 1999, 282(24): 2305-2312.
  • 4Wu C, Zhang H, Qian Y, et al. Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition[J]. J Clin Pharm Ther, 2013, 38(4): 321-326.
  • 5Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double- blind, randomized, placebo-controlled studies[J]. Kidney Int, 2004, 66(3): 1153-1158.
  • 6Tamori A, Enomoto M, Kobayashi S, et al. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus[J]. J Viral Hepat, 2010, 17(2): 123-129.
  • 7Kim YJ, Cho HC, Sinn DH, et al. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients[J]. J Gastroenterol Hepatol, 2012, 27 (2) : 306-312.
  • 8Law ST, Li KK, Ho YY. Acquired Fanconi syndrome associated with prolonged adefovir dipivoxil therapy in a chronic hepatitis B patient[J]. Am J Ther, 2013, 20(6): e713-716.
  • 9Jtmg YK, Yeon JE, Choi JH, et al. Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient[J]. Gut Liver, 2010, 4(3): 389-393.
  • 10荣春芳,张云霞.慢性乙型肝炎抗病毒药物研究进展[J].山东医药,2009,49(35):115-116. 被引量:9

共引文献31

同被引文献17

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部